PharmaShots | Incisive News in 3 Shots

Subscribe Now

New Class

Lilly's Reyvow (lasmiditan) Receives FDA's Approval as the First Therapy in a New Class of Acute Treatment for Migraine

Lilly's Reyvow (lasmiditan) Receives FDA's Approval as the First Therapy in a New Class of Acute Treatment for Migraine

October 14, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us